Respiratory Drugs and Devices Market
Respiratory Drugs and Devices Market Size, Share & Trends Analysis By Respiratory Drugs (Anticholinergics, Antihistamines, Beta2 Agonists, Antiasthmatic Combinations, Corticosteroids, Leukotriene Inhibitors, Mast Cell Stabilizers, Phosphodiesterase 4 (Pde4) Inhibitors, Bronchodilators, Decongestants, Expectorants, and Other Respiratory Drugs), By Product Type (Therapeutic Devices, Diagnostic And Monitoring Devices, and Consumables And Accessories), and By End User ( Hospitals, Home Care, and Others), Forecast Period (2026-2035)
Industry Overview
Respiratory drugs and devices market was valued at $55.4 billion in 2025 and is projected to reach $82.9 billion by 2035, growing at a CAGR of 4.2% during the forecast period (2026-2035). The market is witnessing steady growth driven by the rising prevalence of chronic respiratory diseases such as asthma, COPD, and pulmonary fibrosis. Increasing air pollution, aging populations, and changing lifestyles have elevated the global burden of respiratory disorders, fueling demand for effective treatments and advanced respiratory care equipment. Continuous technological advancements, including smart inhalers, AI-integrated ventilators, and digital monitoring systems, are transforming disease management and patient outcomes. Moreover, growing healthcare investments, supportive government initiatives, and strong innovation from key industry players are further propelling the market’s expansion across both developed and emerging regions.
Market Dynamics
Rising Prevalence of Chronic Respiratory Diseases
The escalating incidence of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and sleep apnea remains a major driver of the global respiratory drugs and devices market. According to the World Health Organization (WHO), COPD alone is among the top causes of death globally, affecting hundreds of millions each year. Factors such as urbanization, industrial pollution, smoking habits, and exposure to indoor air pollutants have intensified respiratory health challenges, especially in developing countries. The increasing disease burden has led to a growing need for advanced inhaled drugs, nebulizers, and mechanical ventilation systems. Moreover, the rising geriatric population is more vulnerable to respiratory infections, further supporting sustained demand for both therapeutic drugs and respiratory care devices across hospital and home-care settings.
Technological Advancements and Digital Integration in Respiratory Care
Technological innovation is reshaping the respiratory drugs and devices landscape. The introduction of smart inhalers, AI-based ventilators, and connected nebulization systems has revolutionized patient monitoring and treatment adherence. Digital integration allows physicians to track patient data remotely, enabling better disease management and reducing hospital readmissions. For instance, sensor-enabled inhalers can record dose usage and transmit data via mobile apps, improving patient compliance and outcomes. Furthermore, advancements in biologic therapies and combination inhalers provide targeted treatments for severe asthma and COPD, thereby expanding pharmaceutical revenues. This convergence of digital technology and respiratory medicine is creating new growth opportunities and improving healthcare efficiency globally.
Government Initiatives, Healthcare Spending, and Pandemic Preparedness
Global health authorities and governments are increasingly investing in respiratory healthcare infrastructure and awareness programs. The COVID-19 pandemic emphasized the importance of respiratory support systems, prompting substantial investments in ventilators, oxygen therapy equipment, and critical-care devices. Many governments have since introduced reimbursement policies and funding initiatives to improve access to respiratory drugs and devices. Additionally, pharmaceutical companies are collaborating with healthcare institutions to expand manufacturing and distribution networks, ensuring preparedness for future respiratory emergencies. Enhanced healthcare spending, coupled with supportive regulatory frameworks, continues to bolster innovation and accessibility in the global respiratory drugs and devices market.
Market Segmentation
- Based on the respiratory drugs, the market is segmented into anticholinergics, antihistamines, beta2 agonists, antiasthmatic combinations, corticosteroids, leukotriene inhibitors, mast cell stabilizers, phosphodiesterase 4 (Pde4) inhibitors, bronchodilators, decongestants, expectorants, and other respiratory drugs.
- Based on the product type, the market is segmented into therapeutic devices, diagnostic and monitoring devices, and consumables and accessories.
- Based on the end-user, the market is segmented into hospitals, home care, and others.
Therapeutic Devices Segment to Grow at a Considerable Market Share
The therapeutic devices segment is expected to lead the Global Respiratory Drugs and Devices Market with the largest share during the forecast period. This dominance is primarily driven by the rising prevalence of chronic respiratory diseases such as asthma, COPD, and sleep apnea, coupled with the increasing demand for non-invasive and portable respiratory care equipment. Therapeutic devices, including ventilators, positive airway pressure (PAP) devices, nebulizers, oxygen concentrators, and inhalers, form the backbone of both acute and long-term respiratory management. The segment benefits from technological innovations such as smart, digitally connected devices that enable remote monitoring, data tracking, and improved patient compliance. The COVID-19 pandemic also accelerated the global demand for ventilators and oxygen delivery systems, highlighting the vital role of therapeutic devices in critical care settings.
Furthermore, the expanding use of home healthcare services has led to significant adoption of compact and user-friendly respiratory devices for chronic disease management. Among therapeutic devices, inhalers and PAP systems contribute significantly to revenue due to their broad usage in outpatient and home-care applications. Growing healthcare expenditure, the rise in geriatric populations, and increased awareness regarding early respiratory disease management continue to reinforce this segment’s dominance. As healthcare systems emphasize preventive care and home-based treatment, the therapeutic devices segment remains the cornerstone of the market, capturing the largest share globally.
Hospitals: A Key Segment in Market Growth
Among all the segments of the global respiratory drugs and devices market, the hospitals segment under the end-user category is expected to dominate market growth during the forecast period. Hospitals serve as the primary point of diagnosis and treatment for acute and chronic respiratory conditions such as asthma, COPD, pulmonary fibrosis, and acute respiratory distress syndrome (ARDS). The increasing prevalence of these diseases, combined with a rise in hospitalization rates linked to pollution, smoking, and infectious outbreaks, has significantly boosted the demand for advanced respiratory care equipment and therapeutics within hospital settings. Hospitals also remain the leading purchasers of ventilators, oxygen therapy systems, nebulizers, and advanced monitoring devices, as these are essential for managing critical respiratory conditions.
Furthermore, the growing integration of smart and AI-based ventilators, digital monitoring tools, and connected inhaler systems in hospital infrastructure is enhancing treatment precision and patient outcomes. The expansion of intensive care units (ICUs) and respiratory wards worldwide, especially after the COVID-19 pandemic, has further accelerated the adoption of sophisticated respiratory management solutions.
Regional Outlook
The global respiratory drugs and devices market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Region to Hold a Substantial Growth Rate
In North America, the US dominates the global respiratory drugs and devices market, accounting for the largest share in terms of revenue and technological advancement. The country’s leadership position can be attributed to a combination of factors, including a high prevalence of chronic respiratory diseases, advanced healthcare infrastructure, substantial research and development (R&D) investment, and a strong presence of leading pharmaceutical and medical device companies. According to the Centers for Disease Control and Prevention (CDC), millions of Americans suffer from asthma and chronic obstructive pulmonary disease (COPD), which collectively represent a significant public health burden. This high disease incidence fuels continuous demand for both innovative respiratory drugs and technologically advanced devices such as ventilators, inhalers, nebulizers, and oxygen therapy systems.
The US healthcare system also benefits from early adoption of digital respiratory technologies, including smart inhalers, AI-integrated ventilators, and connected monitoring systems that enhance treatment adherence and patient outcomes. Major market players such as GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Philips Healthcare, ResMed, Medtronic, and GE Healthcare have established robust manufacturing, distribution, and R&D networks across the country. These companies leverage the strong regulatory and funding environment to introduce advanced respiratory therapies and device innovations.
Market Players Outlook
The major companies operating in the global respiratory drugs and devices market include AstraZeneca plc, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Koninklijke Philips N.V., Novartis AG, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.
Recent Developments
- In July 2025, the FDA approved Jascayd (nerandomilast) tablets for the treatment of idiopathic pulmonary fibrosis (IPF), marking the first new therapy for this serious lung condition in over a decade. IPF leads to thickening and stiffening of lung tissue, resulting in permanent scarring that impairs breathing, with common symptoms including shortness of breath and cough. The condition mainly affects individuals aged 60 to 70 years and can progress at varying rates.
- In May 2025, Trixeo Aerosphere, AstraZeneca's fixed-dose triple-combination therapy for COPD, was approved in the UK for use with a next-generation propellant that has near-zero Global Warming Potential (GWP). This propellant offers a 99.9% reduction in GWP compared to current options used in metered-dose inhalers. The approval by the UK Medicines and Healthcare Products Regulatory Agency was supported by clinical data showing bioequivalence with the existing propellant, maintaining the medicine's safety and tolerability profile. Trixeo is also marketed as Breztri Aerosphere in the US, China, and Japan.
The Report Covers
- Market value data analysis for 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global respiratory drugs and devices market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Respiratory Drugs and Devices Market Sales Analysis – Respiratory Drugs | Respiratory Drugs | End User ($ Million)
- Respiratory Drugs and Devices Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Respiratory Drugs and Devices Market Trends
- Market Recommendations
- Market Determinants
- Market Drivers
- Drivers For Global Respiratory Drugs and Devices Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Respiratory Drugs and Devices Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Respiratory Drugs and Devices Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Respiratory Drugs and Devices Market Revenue and Share by Manufacturers
- Respiratory Drugs and Devices Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- AstraZeneca plc
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Boehringer Ingelheim GmbH
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- GlaxoSmithKline plc
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Koninklijke Philips N.V.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Novartis AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- AstraZeneca plc
- Key Company Analysis
- Global Respiratory Drugs and Devices Market Sales Analysis by Respiratory Drugs ($ Million)
- Anticholinergics
- Antihistamines
- Beta2 Agonists
- Antiasthmatic Combinations
- Corticosteroids
- Leukotriene Inhibitors
- Mast Cell Stabilizers
- Phosphodiesterase 4 (Pde4) Inhibitors
- Bronchodilators
- Decongestants
- Expectorants
- Other Respiratory Drugs
- Global Respiratory Drugs and Devices Market Sales Analysis by Respiratory Drugs ($ Million)
- Therapeutic Devices
- Positive Airway Pressure Devices
- Masks
- Ventilators
- Nebulizers
- Humidifiers
- Oxygen Concentrators
- Inhalers
- Resuscitators
- Nitric Oxide Delivery Units
- Respiratory Oxygen Hoods
- Diagnostic And Monitoring Devices
- Respiratory Pulse Oximeters
- Respiratory Capnographs
- Respiratory Gas Analysers
- Respiratory Spirometers
- Respiratory Polysomnography (Psg) Devices
- Respiratory Peak Flow Meters
- Consumables And Accessories
- Disposable Masks
- Tracheostomy Tubes
- Nasal Cannulas & Other Consumables And Accessories
- Therapeutic Devices
- Global Respiratory Drugs and Devices Market Sales Analysis by End User ($ Million)
- Hospitals
- Home Care
- Others
- Regional Analysis
- North American Respiratory Drugs and Devices Market Sales Analysis – Respiratory Drugs | Respiratory Drugs | End User | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Respiratory Drugs and Devices Market Sales Analysis – Respiratory Drugs | Respiratory Drugs | End User | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Respiratory Drugs and Devices Market Sales Analysis – Respiratory Drugs | Respiratory Drugs | End User | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Respiratory Drugs and Devices Market Sales Analysis – Respiratory Drugs | Respiratory Drugs | End User | Country ($ Million)
- Macroeconomic Factors for the Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- 3M Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Beximco Pharmaceuticals Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Boehringer Ingelheim GmbH
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Chiesi Farmaceutici S.p.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cipla Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Drägerwerk AG & Co. KGaA
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Fisher & Paykel Healthcare Corp. Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GE HealthCare Technologies Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GlaxoSmithKline plc (GSK)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Masimo Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Medtronic plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co., Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Philips Healthcare
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- ResMed Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Teva Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Vyaire Medical Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- 3M Co.
1. Global Respiratory Drugs Market Research and Analysis by Drugs, 2025–2035 ($ Million)
2. Global Anticholinergics Respiratory Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Antihistamines Respiratory Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Beta2 Agonists Respiratory Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Antiasthmatic Combinations Respiratory Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Corticosteroids Respiratory Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Leukotriene Inhibitors Respiratory Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Mast Cell Stabilizers Respiratory Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Phosphodiesterase 4 (PDE4) Inhibitors Respiratory Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Bronchodilators Respiratory Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Decongestants Respiratory Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Expectorants Respiratory Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
13. Global Other Respiratory Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
14. Global Respiratory Therapeutic Devices Market Research and Analysis by Region, 2025–2035 ($ Million)
15. Global Positive Airway Pressure Devices Market Research and Analysis by Region, 2025–2035 ($ Million)
16. Global Respiratory Masks Market Research and Analysis by Region, 2025–2035 ($ Million)
17. Global Ventilators Market Research and Analysis by Region, 2025–2035 ($ Million)
18. Global Nebulizers Market Research and Analysis by Region, 2025–2035 ($ Million)
19. Global Humidifiers Market Research and Analysis by Region, 2025–2035 ($ Million)
20. Global Oxygen Concentrators Market Research and Analysis by Region, 2025–2035 ($ Million)
21. Global Inhalers Market Research and Analysis by Region, 2025–2035 ($ Million)
22. Global Resuscitators Market Research and Analysis by Region, 2025–2035 ($ Million)
23. Global Nitric Oxide Delivery Units Market Research and Analysis by Region, 2025–2035 ($ Million)
24. Global Respiratory Oxygen Hoods Market Research and Analysis by Region, 2025–2035 ($ Million)
25. Global Respiratory Diagnostic and Monitoring Market Research and Analysis by Region, 2025–2035 ($ Million)
26. Global Respiratory Pulse Oximeters Market Research and Analysis by Region, 2025–2035 ($ Million)
27. Global Respiratory Capnographs Market Research and Analysis by Region, 2025–2035 ($ Million)
28. Global Respiratory Gas Analysers Market Research and Analysis by Region, 2025–2035 ($ Million)
29. Global Respiratory Spirometers Market Research and Analysis by Region, 2025–2035 ($ Million)
30. Global Respiratory Polysomnography (PSG) Devices Market Research and Analysis by Region, 2025–2035 ($ Million)
31. Global Respiratory Peak Flow Meters Market Research and Analysis by Region, 2025–2035 ($ Million)
32. Global Respiratory Consumables and Accessories Market Research and Analysis by Region, 2025–2035 ($ Million)
33. Global Disposable Masks Market Research and Analysis by Region, 2025–2035 ($ Million)
34. Global Tracheostomy Tubes Market Research and Analysis by Region, 2025–2035 ($ Million)
35. Global Nasal Cannulas & Other Consumables and Accessories Market Research and Analysis by Region, 2025–2035 ($ Million)
36. Global Respiratory Drugs and Devices Market Research and Analysis by End User, 2025–2035 ($ Million)
37. Global Respiratory Drugs and Devices For Hospitals Market Research and Analysis by Region, 2025–2035 ($ Million)
38. Global Respiratory Drugs and Devices For Home Care Market Research and Analysis by Region, 2025–2035 ($ Million)
39. Global Respiratory Drugs and Devices For Other End User Market Research and Analysis by Region, 2025–2035 ($ Million)
40. Global Respiratory Drugs and Devices Market Research and Analysis by Region, 2025–2035 ($ Million)
41. North American Respiratory Drugs and Devices Market Research and Analysis by Country, 2025–2035 ($ Million)
42. North American Respiratory Drugs and Devices Market Research and Analysis by Respiratory Drugs, 2025–2035 ($ Million)
43. North American Respiratory Drugs and Devices Market Research and Analysis by Product Type, 2025–2035 ($ Million)
44. North American Respiratory Drugs and Devices Market Research and Analysis by End User, 2025–2035 ($ Million)
45. European Respiratory Drugs and Devices Market Research and Analysis by Country, 2025–2035 ($ Million)
46. European Respiratory Drugs and Devices Market Research and Analysis by Respiratory Drugs, 2025–2035 ($ Million)
47. European Respiratory Drugs and Devices Market Research and Analysis by Product Type, 2025–2035 ($ Million)
48. European Respiratory Drugs and Devices Market Research and Analysis by End User, 2025–2035 ($ Million)
49. Asia-Pacific Respiratory Drugs and Devices Market Research and Analysis by Country, 2025–2035 ($ Million)
50. Asia-Pacific Respiratory Drugs and Devices Market Research and Analysis by Respiratory Drugs, 2025–2035 ($ Million)
51. Asia-Pacific Respiratory Drugs and Devices Market Research and Analysis by Product Type, 2025–2035 ($ Million)
52. Asia-Pacific Respiratory Drugs and Devices Market Research and Analysis by End User, 2025–2035 ($ Million)
53. Rest of the World Respiratory Drugs and Devices Market Research and Analysis by Region, 2025–2035 ($ Million)
54. Rest of the World Respiratory Drugs and Devices Market Research and Analysis by Respiratory Drugs, 2025–2035 ($ Million)
55. Rest of the World Respiratory Drugs and Devices Market Research and Analysis by Product Type, 2025–2035 ($ Million)
56. Rest of the World Respiratory Drugs and Devices Market Research and Analysis by End User, 2025–2035 ($ Million)
1. Global Respiratory Drugs and Devices Market Share by Respiratory Drugs, 2025 Vs 2035 (%)
2. Global Anticholinergics Respiratory Drugs Market Share by Region, 2025 Vs 2035 (%)
3. Global Antihistamines Respiratory Drugs Market Share by Region, 2025 Vs 2035 (%)
4. Global Beta2 Agonists Respiratory Drugs Market Share by Region, 2025 Vs 2035 (%)
5. Global Antiasthmatic Combinations Respiratory Drugs and Devices Market Share by Region, 2025 Vs 2035 (%)
6. Global Corticosteroids Respiratory Drugs Market Share by Region, 2025 Vs 2035 (%)
7. Global Leukotriene Inhibitors Respiratory Drugs Market Share by Region, 2025 Vs 2035 (%)
8. Global Mast Cell Stabilizers Respiratory Drugs Market Share by Region, 2025 Vs 2035 (%)
9. Global Phosphodiesterase 4 (PDE4) Inhibitors Respiratory Drugs Market Share by Region, 2025 Vs 2035 (%)
10. Global Bronchodilators Respiratory Drugs Market Share by Region, 2025 Vs 2035 (%)
11. Global Decongestants Respiratory Drugs Market Share by Region, 2025 Vs 2035 (%)
12. Global Expectorants Respiratory Drugs Market Share by Region, 2025 Vs 2035 (%)
13. Global Other Respiratory Drugs Market Share by Region, 2025 Vs 2035 (%)
14. Global Respiratory Therapeutic Devices Market Share by Region, 2025 Vs 2035 (%)
15. Global Positive Airway Pressure Devices Market Share by Region, 2025 Vs 2035 (%)
16. Global Respiratory Masks Market Share by Region, 2025 Vs 2035 (%)
17. Global Ventilators Market Share by Region, 2025 Vs 2035 (%)
18. Global Nebulizers Market Share by Region, 2025 Vs 2035 (%)
19. Global Humidifiers Market Share by Region, 2025 Vs 2035 (%)
20. Global Oxygen Concentrators Market Share by Region, 2025 Vs 2035 (%)
21. Global Inhalers Market Share by Region, 2025 Vs 2035 (%)
22. Global Resuscitators Market Share by Region, 2025 Vs 2035 (%)
23. Global Nitric Oxide Delivery Units Market Share by Region, 2025 Vs 2035 (%)
24. Global Respiratory Oxygen Hoods Market Share by Region, 2025 Vs 2035 (%)
25. Global Respiratory Diagnostic and Monitoring Devices Market Share by Region, 2025 Vs 2035 (%)
26. Global Respiratory Pulse Oximeters Market Share by Region, 2025 Vs 2035 (%)
27. Global Respiratory Capnographs Market Share by Region, 2025 Vs 2035 (%)
28. Global Respiratory Gas Analysers Market Share by Region, 2025 Vs 2035 (%)
29. Global Respiratory Spirometers Market Share by Region, 2025 Vs 2035 (%)
30. Global Respiratory Polysomnography (PSG) Devices Market Share by Region, 2025 Vs 2035 (%)
31. Global Respiratory Peak Flow Meters Market Share by Region, 2025 Vs 2035 (%)
32. Global Respiratory Consumables and Accessories Market Share by Region, 2025 Vs 2035 (%)
33. Global Disposable Masks Market Share by Region, 2025 Vs 2035 (%)
34. Global Tracheostomy Tubes Market Share by Region, 2025 Vs 2035 (%)
35. Global Nasal Cannulas & Other Consumables and Accessories Market Share by Region, 2025 Vs 2035 (%)
36. Global Respiratory Drugs and Devices Market Share by End User, 2025 Vs 2035 (%)
37. Global Respiratory Drugs and Devices For Hospitals Market Share by Region, 2025 Vs 2035 (%)
38. Global Respiratory Drugs and Devices For Home Care Market Share by Region, 2025 Vs 2035 (%)
39. Global Respiratory Drugs and Devices For End User Market Share by Region, 2025 Vs 2035 (%)
40. Global Respiratory Drugs and Devices Market Share by Region, 2025 Vs 2035 (%)
41. US Respiratory Drugs and Devices Market Size, 2025–2035 ($ Million)
42. Canada Respiratory Drugs and Devices Market Size, 2025–2035 ($ Million)
43. UK Respiratory Drugs and Devices Market Size, 2025–2035 ($ Million)
44. France Respiratory Drugs and Devices Market Size, 2025–2035 ($ Million)
45. Germany Respiratory Drugs and Devices Market Size, 2025–2035 ($ Million)
46. Italy Respiratory Drugs and Devices Market Size, 2025–2035 ($ Million)
47. Spain Respiratory Drugs and Devices Market Size, 2025–2035 ($ Million)
48. Russia Respiratory Drugs and Devices Market Size, 2025–2035 ($ Million)
49. Rest of Europe Respiratory Drugs and Devices Market Size, 2025–2035 ($ Million)
50. India Respiratory Drugs and Devices Market Size, 2025–2035 ($ Million)
51. China Respiratory Drugs and Devices Market Size, 2025–2035 ($ Million)
52. Japan Respiratory Drugs and Devices Market Size, 2025–2035 ($ Million)
53. South Korea Respiratory Drugs and Devices Market Size, 2025–2035 ($ Million)
54. Australia and New Zealand Respiratory Drugs and Devices Market Size, 2025–2035 ($ Million)
55. ASEAN Economies Respiratory Drugs and Devices Market Size, 2025–2035 ($ Million)
56. Rest of Asia-Pacific Respiratory Drugs and Devices Market Size, 2025–2035 ($ Million)
57. Latin America Respiratory Drugs and Devices Market Size, 2025–2035 ($ Million)
58. Middle East and Africa Respiratory Drugs and Devices Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Respiratory Drugs & Devices Market in 2025 is estimated to be around $55.4 billion.
North America holds the largest share in the Respiratory Drugs & Devices Market.
Leading players in the Respiratory Drugs & Devices Market include AstraZeneca plc, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Koninklijke Philips N.V., Novartis AG, among others.
Respiratory Drugs & Devices Market is expected to grow at a CAGR of 4.2% from 2026 to 2035.
Increasing prevalence of respiratory disorders, rising air pollution and smoking, growing use of advanced inhalation devices, and ongoing drug innovations are driving market growth.
